Literature DB >> 15051503

Targeting the single-strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells.

Masood A Shammas1, Xiaohai Liu, Gérald Gavory, Kevin D Raney, Shankar Balasubramanian, Robert J Shmookler Reis.   

Abstract

Telomeres are believed to stabilize chromosomes through several mechanisms that are dependent upon specific DNA-DNA and protein-DNA interactions. Telomeres are maintained by the enzyme telomerase. Telomerase activity, which is below detectable level in almost all types of diploid cells, is re-activated in most immortal and cancer cells. For this study, we designed peptide nucleic acid (PNA) oligonucleotides targeted to the telomeric G-rich strand, and tested their efficacy to reverse the immortality of transformed human fibroblasts. Anti-telomere PNAs, transfected into human fibroblasts along with a selectable marker, resulted in a significant reduction in colony size and elicited cell death by apoptosis. This PNA inhibitor does not inhibit telomerase activity in vitro, suggesting a distinct cellular mechanism from known PNA inhibitors. A combination of this class of PNA inhibitor with a PNA that does block telomerase activity resulted in nearly complete inhibition of colony growth, induction of apoptosis, and an apparent reduction in telomere length. Each effect was greater than that evoked by either agent alone, indicating enhanced efficacy for therapeutic approaches that target multiple, distinct mechanism of telomere maintenance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051503     DOI: 10.1016/j.yexcr.2004.01.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome.

Authors:  Snehlata Tripathi; Binay Chaubey; Beverly E Barton; Virendra N Pandey
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

2.  Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Authors:  Masood A Shammas; Aamer Qazi; Ramesh B Batchu; Robert C Bertheau; Jason Y Y Wong; Manjula Y Rao; Madhu Prasad; Diptiman Chanda; Selvarangan Ponnazhagan; Kenneth C Anderson; Christopher P Steffes; Nikhil C Munshi; Immaculata De Vivo; David G Beer; Sergei Gryaznov; Donald W Weaver; Raj K Goyal
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

Review 4.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

5.  Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.

Authors:  Masood A Shammas; Robert J Shmookler Reis; Hemanta Koley; Ramesh B Batchu; Cheng Li; Nikhil C Munshi
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

6.  Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Authors:  M A Shammas; H Koley; R C Bertheau; P Neri; M Fulciniti; P Tassone; S Blotta; A Protopopov; C Mitsiades; R B Batchu; K C Anderson; A Chin; S Gryaznov; N C Munshi
Journal:  Leukemia       Date:  2008-05-01       Impact factor: 11.528

7.  Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.

Authors:  R Lu; J Pal; L Buon; P Nanjappa; J Shi; M Fulciniti; Y-T Tai; L Guo; M Yu; S Gryaznov; N C Munshi; M A Shammas
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.